Risdiplam for treating spinal muscular atrophy in children and adults - Appraisal consultation document

In DRAFT guidance, NICE does not recommend risdiplam for spinal muscular atrophy as there were significant uncertainties in the evidence, and the cost-effectiveness estimates were much higher than what is usually considered an acceptable use of NHS resources.

Source:

National Institute for Health and Care Excellence